Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera
Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat
The biopharma industry has lost another leading figure with the passing of Andy Zoltners, co-founder of ZS Associates, on the 40th anniversary of the company.
Senior lawmakers in the US across both sides of the political divide have released a list of measures that they are considering to reduce medicine costs for patients and t
Amgen has won a crunch appeals court ruling that delays generic competition to its big-selling psoriasis drug Otezla in the US until 2028, although it missed out on gettin
AbbVie has carved out a niche for its migraine drug Qulipta in a competitive market, after claiming FDA approval for the product in the prevention of chronic migraine.
AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut